• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CRISPR Therapeutics (CRSP) Stock May Command A Premium On Its Equity Base

    Simply Wall St·10/02/2026 01:19:42
    Listen to the news

    CRISPR Therapeutics has delivered a mixed share price story over the past few years, and that uneven run puts fresh attention on what investors are really paying for on its balance sheet. With the stock now around US$55, the key issue is how that market value lines up against the company’s book value today.

    • Over the past 5 years the share price has fallen 46.2%, which puts long term holders in focus and raises the question of whether the current valuation is still anchored to the underlying equity in the business.
    • As a clinical stage biotech that relies heavily on its research pipeline and cash reserves, shifts in expectations for trial progress, future revenue timing or funding needs can quickly change how much weight investors put on book value as a guide.
    • Your read on CRISPR Therapeutics is one view; the desks covering it have another. See what analysts think CRISPR Therapeutics's shares could be worth.

    The issue now is whether the current market price for CRISPR Therapeutics is adequately supported by the book value on its balance sheet.

    If you are weighing CRISPR Therapeutics against other balance sheet focused ideas, it can help to compare it with solid balance sheet and fundamentals stocks screener (25 results).

    Is CRISPR Therapeutics Getting Expensive on Book Value?

    P/B is a useful lens for CRISPR Therapeutics because the balance sheet, not current profits, does most of the work in anchoring the valuation. On that score, the stock trades at about 3.1x book value, above the Biotechs sector average of roughly 2.1x. That gap implies investors are paying a higher price for each dollar of net assets than they are for the typical listed peer.

    Compared with a peer group that averages close to 10.0x P/B, CRISPR Therapeutics looks lower on this measure, yet still screens overvalued against the broader industry benchmark. For anyone thinking about paying that premium, the key question is whether the research pipeline, cash position, and future optionality justify paying more than the sector norm for the current equity base. Explore the numbers behind CRISPR Therapeutics's P/B valuation.

    NasdaqGM:CRSP P/B Ratio as at Oct 2026
    NasdaqGM:CRSP P/B Ratio as at Oct 2026

    The CRISPR Therapeutics Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives for CRISPR Therapeutics pick up where the price to book puzzle leaves off by explaining which growth, margin and earnings paths would need to occur for the stock to be worth materially more or materially less than it is today on the market. Each narrative links its number to a concrete, testable view of how CRISPR Therapeutics' growth, profitability and risk profile might evolve, which you can track against fresh information on the Community page over time.

    One of the top community narratives on CRISPR Therapeutics: 37% undervalued

    "The main requirement for success is effective late-stage clinical execution for CTX310, CTX611, and zugo-cel, alongside managing competition..."

    Discover why this Narrative puts CRISPR Therapeutics at 37% undervalued.

    One more crucial piece before you judge CRISPR Therapeutics on valuation alone

    Price to book gives only part of the picture for CRISPR Therapeutics, because analyst projections for where this business could be in a few years offer a separate reference point to compare with today’s market value. Explore where analysts expect CRISPR Therapeutics to be in a few years.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.